Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
Mult Scler
; 29(3): 471-474, 2023 Mar.
Article
en En
| MEDLINE
| ID: mdl-35957594
ABSTRACT
BACKGROUND:
There is concern that immune checkpoint inhibitors (ICPIs) can provoke relapses in people with multiple sclerosis (pwMS).OBJECTIVE:
Analyze outcomes of pwMS who received ICPI treatment for malignancy.METHODS:
We electronically identified pwMS who received ICPI treatment at Mass General Brigham hospital system. We retrospectively obtained information about patients' MS, cancer, treatment, and outcomes.RESULTS:
Sixteen patients were identified with an average (standard deviation (SD)) age of 67.4 (11.9) years. Eleven (68.8%) had no relapses since MS diagnosis. None had MS relapses after ICPI treatment or new MS lesions.CONCLUSION:
ICPI use was not associated with increased clinical disease activity in this cohort of older patients with inactive MS.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple
/
Neoplasias
/
Enfermedades del Sistema Nervioso
Límite:
Aged
/
Humans
Idioma:
En
Revista:
Mult Scler
Asunto de la revista:
NEUROLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos